12/15-Lipoxygenase (12/15-LO) is an enzyme that converts polyunsaturated fatty acids into bioactive lipid derivatives. In this study, we showed that inhibition of 12/15-LO by baicalein (BA) significantly attenuated clinical severity of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Inhibited migration of autoimmune T cells into the central nervous system (CNS) by BA treatment could be attributed to reduced activation of microglia, which was indicated by suppressed phagocytosis, and decreased production of proinflammatory cytokines and chemokines in the CNS. We further observed that inhibition of 12/15-LO with BA led to increased expression of peroxisome proliferator-activated receptor (PPAR)b/ d in microglia of EAE mice. This was confirmed in vitro in primary microglia and a microglia cell line, BV2. In addition, we demonstrated that BA did not affect 12/15-LO or 5-lipoxygenase (5-LO) expression in microglia, but significantly decreased 12/ 15-LO products without influencing the levels of 5-LO metabolites. Moreover, among these compounds only 12/15-LO metabolite 12-hydroxyeicosatetraenoic acid was able to reverse BA-mediated upregulation of PPARb/d in BV2 cells. We also showed that inhibition of microglia activation by PPARb/d was associated with repressed NF-jB and MAPK activities. Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system (CNS) resulting in motor and sensory deficits. Altered plasma lipid profiles were found in many MS patients, 1 suggesting a role of lipids in pathogenesis of MS. For example, in active MS, there is a shift in the lipid composition of normal appearing white matter and normal appearing grey matter to a higher phospholipid and lower sphingolipid content, which indicates a metabolic defect that causes sphingolipids to be shuttled to phospholipid production in MS patients.
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system (CNS) resulting in motor and sensory deficits. Altered plasma lipid profiles were found in many MS patients, 1 suggesting a role of lipids in pathogenesis of MS. For example, in active MS, there is a shift in the lipid composition of normal appearing white matter and normal appearing grey matter to a higher phospholipid and lower sphingolipid content, which indicates a metabolic defect that causes sphingolipids to be shuttled to phospholipid production in MS patients. 2 Experimental autoimmune encephalomyelitis (EAE) is a commonly used animal model for MS. Autoreactive T helper (Th) 1 and Th17 cells responding to myelin proteins are implicated in the pathogenesis of MS and EAE, 3, 4 and CNS-activated microglia are thought to participate in myelin loss and lesion formation. 5 It is evident that disregulation of lipid metabolism is linked with disease progression of EAE. For example, anandamide is a derivative of arachidonic acid, fatty acid amide hydrolase and epidermal fatty acid-binding protein are involved in the degradation and transportation of anandamide respectively. 6 Genetic deletion of fatty acid amide hydrolase resulted in improved long-term outcome in chronic autoimmune encephalitis, 7 and mice deficient in epidermal fatty acid-binding protein developed milder EAE. 8 12/15-Lipoxygenase (12/15-LO) belongs to a family of enzymes that can metabolize arachidonic acid to generate corresponding hydroxides such as 12-hydroxyeicosatetraenoic acid (12-HETE) and 15-HETE. 9, 10 Arachidonic acid and its lipid metabolites have important roles in human inflammatory diseases, [11] [12] [13] which suggests that 12/15-LO can be a pathogenic player that mediates inflammatory responses in vivo. 12/15-LO is widely expressed in the CNS, 14, 15 and has been demonstrated to be involved in the pathogenesis of various neurological diseases. [16] [17] [18] [19] 12/15-LO exerts a regulatory role in Alzheimer's disease, an inflammatory and neurodegenerative disease. 16, 17 Li et al. 18 demonstrated that decreased neuronal concentrations of the anti-oxidant glutathione, an early biomarker in Parkinson's disease, was associated with 12/15-LO activation. A recent study reported that 12/15-LO-deficient mice showed a late but severe clinical symptom as compared with wild-type mice. 19 However, the authors did not address the underlying cellular and molecular mechanisms directly. Thus, the exact role of 12/15-LO in EAE remains unresolved.
The peroxisome proliferator-activated receptors (PPARs) are a family of three ligand-activated transcription factors: PPARa, PPARb/d and PPARg. All the PPARs have critical roles in regulation of development and energy homeostasis. 20 Recently, there has been a great deal of interest in the involvement of PPARs in inflammatory processes. 21 In particular, PPARa and PPARg inhibit the activation of inflammatory gene expression and interfere with proinflammatory transcription factor signaling pathways in CNS inflammatory diseases. 22, 23 However, the role of PPARb/d for regulating inflammation is just emerging, and the mechanisms by which PPARb/d affects inflammatory reactions are not well understood.
Baicalein (BA) is a specific and commonly used inhibitor of leukocyte 12/15-LO. 24, 25 In this study, we examined the role of 12/15-LO in regulating inflammatory responses during pathogenesis of EAE. We found that on selective inhibition of 12/15-LO with BA, mice displayed much milder EAE symptoms despite their competent peripheral T-cell response. BA functioned in microglia to promote PPARb/d expression, which in turn inhibited microglia activation, reduced production of proinflammatory cytokines and chemokines, and decreased immune cell infiltration into the CNS. These findings indicate a regulatory role of 12/15-LO in inflammation with potential therapeutic benefits in CNS autoimmune diseases.
Results
The 12/15-LO inhibitor BA ameliorates clinical symptoms of EAE. To investigate the role of 12/15-LO in CNS autoimmune disease, we used BA (75 mg/kg/day), a 12/15-LO inhibitor, by i.p. injection in EAE mice from day 3 preimmunization onward as a preventive protocol. Vehicletreated mice served as controls. BA treatment significantly attenuated the severity of EAE compared with the vehicle control ( Figure 1a) . The effects were noticeable at day 13 post immunization and persisted over the entire course of EAE. Similar effects were observed when treatment began from day 12 post-immunization onward as a treatment protocol (Figure 1b) . The observed clinical effects of BA were consistent with much less infiltration of inflammatory cells and fewer demyelinated plaques in the white matter of BA-treated EAE mice compared with vehicle-treated group (Figure 1c) . Moreover, percentages of inflammatory CD4 þ and CD8
þ T cells that infiltrated into the CNS of naive, vehicle-and BA-treated EAE mice in induction phase were examined (Figure 1d ). We found that BA significantly reduced infiltration of inflammatory T cells into the CNS of EAE mice compared with vehicle control. These data indicate that 12/15-LO inhibitor BA is effective in alleviating the severity of EAE.
BA reduces autoimmune cell infiltration into the CNS. It is known that efficient activation of autoreactive T cells is an obligatory requirement for induction of CNS inflammation and pathology of EAE. 26 We tested whether EAE attenuated by BA was the result of inhibition of T-cell proliferation and cytokine production. Draining lymph nodes (DLNs) and splenocytes were isolated from vehicle-or BA-treated EAE mice for analyses. Proliferation of encephalitogenic T cells was comparable between groups on the myelin oligodendrocyte glycoprotein (MOG) peptide stimulation ex vivo (Figure 2a ). In addition, BA did not alter the capability of encephalitogenic T cells to produce cytokines such as interferon (IFN)-g, interleukin (IL)-4, IL-10 and IL-17, as compared with vehicle control (Figure 2b) .
To further examine the effects of BA on periphery autoimmune cell responses, DLN cells and splenocytes derived from vehicle-or BA-treated EAE mice were isolated, re-stimulated with the MOG peptide in vitro, and adoptively transferred into sublethally irradiated mice. Lymphocytes derived from both groups were able to induce EAE without significant difference (Figure 2c ). In another study, DLN cells and splenocytes from EAE mice were re-stimulated with the MOG peptide in vitro and adoptively transferred into sublethally irradiated mice. These mice then received vehicle or BA treatment from day 7 post transfer. Notably, BA significantly suppressed EAE compared with vehicle control (Figure 2d ). This suggests a possible effect of BA on migration of inflammatory cells into the CNS. To test this, messenger RNAs (mRNAs) encoding inflammation-associated chemokines such as CCL2, CCL3, CCL20 and CXCL10 were examined. BA treatment significantly reduced expression of chemokines in the CNS (Figure 2e ). In addition, expression of the Th1 and Th17 cytokines, IFN-g and IL-17, was reduced in the CNS of BA-treated EAE mice (Figure 2f ). CXCR3 and CCR6, the signature chemokine receptors of Th1 and Th17 cells, were also examined by flow cytometry of CD4 þ T cells derived from the CNS and DLNs. The percentages of CXCR3 þ CD4 þ and CCR6 þ CD4 þ cells were significantly lower in the CNS, but higher in DLN cells of BA-treated EAE mice compared with control mice (Figure 2g ). These results suggest that BA treatment leads to impaired Th1 and Th17 cell migration into the CNS and relative accumulation of these cells in DLNs. Thus, BA treatment ameliorates clinical symptoms of EAE through inhibition of migration of autoimmune T cells into the CNS.
BA suppresses CNS inflammation through inhibition of microglia activation. Microglia and astrocytes are CNSresident cells that have important roles in EAE pathogenesis. [27] [28] [29] [30] On activation, these cells produce proinflammatory factors that are toxic to the CNS and promote infiltration and reactivation of autoimmune cells in the CNS. In this regard, we examined the expression of 12/15-LO in these two cell populations on BA treatment. 12/15-LO was mainly expressed in murine primary microglia rather than astrocytes at both the mRNA and protein levels (Figures 3a and b) . BA treatment did not affect the expression of 12/15-LO in primary microglia, astrocytes or microglia derived from EAE mice (Figures 3a-c) , but significantly reduced 12/15-LO metabolites such as 12-HETE, 13-hydroxyoctadecadienoic acid (13-HODE) and 15-HETE in the culture supernatants of primary microglia (Figure 3d ). Another lipoxygenase isoform, 5-lipoxygenase (5-LO), was also found to be expressed in primary microglia, astrocytes and microglia derived from EAE mice (Figures 3a-c) . BA affected neither 5-LO expression in these cell populations, nor its metabolites leukotriene B4 (LTB4) or leukotriene D4 (LTD4) in the culture supernatants of primary microglia (Figures 3a-d) . These data indicate that BA is able to selectively inhibit 12/15-LO activity in microglia. Electron microscopy (EM) was then used to observe the status of microglia. Figure 3e showed microglia in a demyelinated region from vehicle-treated EAE mice. These cells presented long cisternae of granular endoplasmic reticulum and more irregular cell body shapes and exhibited phagocytosis of destroyed myelin and cellular debris. BA treatment suppressed phagocytosis by microglia, as characterized by fewer fragments in the cytoplasm, suggesting impaired microglia activation.
To further elucidate the impact of BA on microglia, we assessed the expression profiles of proinflammatory cytokine and chemokine mRNAs in LPS-stimulated, primary microglia treated with or without BA. Three-hour exposure of microglia to LPS significantly increased expression of proinflammatory cytokines such as tumor necrosis factor (TNF)-a, IL-1b, IL-6 and IL-12p40, and chemokines such as CCL2, CCL3, CCL20 and CXCL10 (Figure 3f ). However, pre-treatment with BA before LPS challenge markedly reduced expression of these factors in a dose-dependent manner (Figure 3f ). By contrast, BA treatment did not reverse the increased proinflammatory gene expression on IFN-g stimulation in primary astrocytes (data not shown). Collectively, these data suggest that the anti-inflammatory property of BA in the CNS of EAE mice is mainly due to its modulatory effects on microglia activation.
BA increases PPARb/d in microglia. PPARs are key modulators of lipid metabolism and exhibit anti-inflammatory effects in EAE. 31 We next investigated expression of PPARs in the CNS and peripheral immune tissues of vehicle-and BA-treated EAE mice. Expression of PPARb/d in the CNS was significantly reduced in the induction and peak phases of EAE. Interestingly, BA treatment significantly reversed PPARb/d expression within the CNS (Figure 4a ), whereas the same treatment did not induce PPARb/d expression in the periphery as detected in DLNs (Figure 4b ). It is known that PPARg can be induced through activation of the 12/15-LO pathway, while suppressed on inhibition of 12/15-LO. 13, 32 Intriguingly, little PPARg protein expression was detected in the CNS of naive mice and EAE mice, and BA treatment did not further reduce PPARg protein levels (Figure 4a ). This indicates that BA has only marginal effects on PPARg expression in the CNS, and it is likely that recovery of PPARb/d in the CNS on BA treatment can have an important role in amelioration of EAE.
As we have demonstrated that BA suppressed EAE through inhibition of microglia activation, we then examined the effect of BA on PPARb/d expression in microglia. The mRNA level of PPARb/d was significantly higher in CD11b þ cells isolated from BA-treated EAE mice compared with control mice (Figure 4c ). In addition, BA increased PPARb/d protein level in primary microglia in a dose-dependent manner (Figure 4d Inhibition of microglia activation by PPARb/d is associated with repression of NF-jB and MAPK activities. We then analyzed whether suppression of microglia activation was due to BA-induced PPARb/d in microglia. Exposure of primary microglia to LPS significantly decreased PPARb/d mRNA (Figure 6a ). However, pre-treatment with BA led to a marked recovery of PPARb/d mRNA level in a dosedependent manner (Figure 6a ). By contrast, BA pretreatment significantly reduced proinflammatory cytokine and chemokine production (Figure 3f ). Thus, PPARb/d expression was negatively associated with production of proinflammatory factors in microglia, implying BA induces PPARb/d to suppress microglia activation. To test the (Figure 6b ). The inhibitory effect of BA on LPSinduced chemokines such as CCL2, CCL3, CCL20 and CXCL10, and proinflammatory cytokines including TNF-a, IL1b, IL-6 and IL-12p40 were abolished on PPARb/d knockdown (Figure 6b ). These results show that PPARb/d induction in microglia via 12/15-LO inhibition was responsible for suppression of microglia activation, indicated by reduced proinflammatory factor expression by microglia, which in turn reduced CNS inflammation in EAE.
To define molecular mechanisms by which BA-induced PPARb/d restricted the proinflammatory responses, we examined the activities of transcription factors, including NFkB and activator protein 1, in microglia cell line BV2. These transcription factors are known downstream components of PPARb/d signaling and are critical for LPS-mediated gene induction. Activation of LPS-stimulated NF-kB was severely attenuated by BA treatment, as indicated by decreased phosphorylation and degradation of IkBa (Figure 6c ). In addition, LPS-dependent phosphorylation of MAPKs, including ERK1/2, p38 and JNK, was also substantially inhibited by BA treatment (Figure 6c ). These results suggest that the antiinflammatory effect of BA-induced PPARb/d was mediated by repression of NF-kB and MAPK activities.
Discussion
In this study, we showed that inhibition of 12/15-LO by BA attenuated CNS inflammation of EAE through increased PPARb/d expression in microglia, which reduced microglia phagocytosis and production of proinflammatory cytokines and chemokines. This in turn impaired recruitment EAE is considered as an autoimmune demyelinating disease of the CNS. Autoreactive T cells, such as Th1 and Th17 cells, are thought to have central roles in the disease process. However, the attenuated severity of EAE by BA was not a result of impaired autoimmune cell responses in the periphery. Administration of BA with both preventive and therapeutic protocols markedly improved the clinical symptoms of EAE with no delay of EAE onset, which suggests that BA does not affect early T-cell activation in the periphery. This hypothesis was further examined by ex vivo analyses of MOG reactivity of encephalomyeltic splenocytes and passive EAE studies. As the reactivation of autoimmune cells by CNS resident, antigen-presenting cell microglia and the recruitment of large numbers of inflammatory cells into the CNS are critical steps in the pathophysiology of EAE, we investigated the status of microglia under BA treatment. We found that BA was able to induce PPARb/d expression in microglia in EAE mice. The induction of PPARb/d in microglia suppressed microglia activation and reduced expression of chemokines CCL2, CCL3, CCL20 and CXCL10, which suppressed CNS inflammation. Induction of PPARb/d by BA was further confirmed in vitro in primary cultures of microglia and a microglia cell line, BV2. In addition, we showed that PPARb/d inhibition of microglia activation was associated with repression of NF-kB and MAPK activities. To our knowledge, the downregulation of PPARb/d by 12/15-LO metabolites in microglia is unprecedented in both physiological and pathological conditions, and our finding could provide a previously uncharacterized approach for treatment of CNS autoimmune diseases.
PPARs are ligand-dependent nuclear receptors that are critical regulators of development and homeostasis by modulating lipid metabolism. 33 Accumulating evidence demonstrates that PPARs exhibit important roles in modulating inflammatory responses. 10, 31, 34 They fine-tune expression of target inflammatory genes through either trans-activation or trans-repression activities. Among the three PPAR family members, the consequences of PPARb/d activation are less well understood. PPARb/d is widely distributed in most tissues with abundant expression in the CNS. 35 Our data indicated that induction of PPARb/d in the CNS, more specifically in microglia, alleviated CNS inflammation of EAE. In contrast to the findings that agonists of PPARg significantly reduce T-cell activation, proliferation and secretion of IFN-g, [36] [37] [38] [39] [40] [41] these results point to a distinct mechanism of action of PPARb/d in amelioration of EAE pathogenesis. Currently, clinical trials of several PPARg agonists are in progress for MS and Alzheimer's disease, and it is necessary to consider whether PPARb/d agonists offer advantages versus treatment with PPARg ligands.
12/15-LO belongs to the lipoxygenase family of enzymes that promote polyunsaturated fatty acids to form a series of biologically active lipid mediators. 9, 10 Based on their phylogenetic classification, murine leukocyte-type 12-LO and human reticulocyte-type 15-LO are highly conserved, sharing about 73% sequence similarity, and belong to the same 12/15-LO subfamily. 42 Expression of murine 12/ 15-LO is limited to a few cell types such as macrophages, endothelial cells and adipocytes, [43] [44] [45] but is highly expressed in macrophages. 43 50 and CNS disorders such as Alzheimer's disease 17 and Parkinson's disease. 18 Here, we further extended the border of research to CNS autoimmune disease by using a pharmaceutical approach to selectively inhibit 12/15-LO by BA. This approach confirmed the pathogenic role of 12/15-LO in EAE, and demonstrated the feasibility of targeting 12/15-LO for treatment of inflammatory diseases in the CNS.
Interestingly, another lipoxygenase isoform, 5-LO, was known to be involved in the pathogenesis of Alzheimer's disease and MS. 51, 52 This study shows that BA only selectively inhibits the enzymatic activities of 12/15-LO but not those of 5-LO. These results, however, do not rule out the possibilities that 5-LO and its metabolites function in MS and EAE in a PPARb/d-independent manner.
Intriguingly, a previous study showed that 12/15-LOdeficient mice developed a late but severe clinical symptom as compared with wild-type mice. 19 The authors detected a major reduction in axons in the cervical spinal cord, but found a very low level of T cells and no macrophages in the hindbrain of 12/15-LO-deficient mice during late active disease. They assumed that inactivation of PPARg might be responsible for the exacerbation of EAE in 12/15-LO-deficient mice, but they did not provide further supporting evidence. In this study, we demonstrate that inhibition of 12/15-LO activity by a selective inhibitor, BA, 23, 25 significantly ameliorate EAE in mice. Abundant PPARb/d but not PPARg expression is induced in the CNS of EAE mice by BA treatment. Moreover, the main metabolite of 12/15-LO, 12-HETE, but not 5-LO metabolites, LTB4 or LTD4, could reverse BA-induced upregulation of PPARb/d in BV2 cells. Thus, our data seem to support that inhibition of 12/15-LO by a pharmacological approach could ameliorate EAE, and we elucidated a possible underlying mechanism.
Recently, it was reported that treatment of mice with a synthetic PPARb/d agonist, GW0742, ameliorated EAE severity.
53 GW0742 did not prevent T-cell activation in the periphery, but it reduced glial cell activation. Another study showed that mice systemically deficient in PPARb/d developed severe EAE symptoms characterized by a striking accumulation of IFN-g þ CD4 þ cells in the spinal cord, significantly higher proliferation and cytokine production of CD4 þ T cells in the periphery, and enhanced expression of IL-12 family cytokines by myeloid cells. 54 Together with our study, these results suggest that different modes of action by PPARb/d in different experimental conditions should be taken into consideration. As we mentioned previously, preferential induction of PPARb/d in CNS-resident microglia formed the underlying mechanism of treatment effects of BA in EAE. Consistently, BA is able to penetrate the blood-brain barrier to distribute in the CNS, and half-life of BA in the brain is about 125% longer than that in the blood, 55 thus we assume that more BA crosses CNS to exert its pharmacological functions as blood-brain barrier is disrupted in the situation of EAE, which form the basis of protective properties of BA in CNS autoimmune diseases.
Among several pathways that have been identified for the anti-inflammatory actions of PPARb/d, inhibition of NF-kB is commonly involved. Inhibition of NF-kB activity by PPARb/d has been shown in endothelial cells, 56 cardiomyocytes 57 and adipocytes. 58 Here, we demonstrated similar mechanisms in microglia, whereby BA-induced PPARb/d in microglia and was associated with repression of NF-kB and MAPK activities. Nevertheless, in addition to inhibition of proinflammatory transcription factors, whether PPARb/d induces anti-inflammatory genes in microglia needs to be further addressed. In this study, we have identified a previously uncharacterized pathway that inhibition of 12/15-LO induces PPARb/d in microglia, which alleviates EAE in mice. This reveals potential therapeutic applications for MS.
Materials and Methods
Induction and treatment of EAE. Female C57BL/6 mice (6-8 weeks of age) were purchased from the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences (Shanghai, China), and were kept under specific pathogenfree conditions in the animal center of Shanghai Jiao Tong University School of Medicine (Shanghai, China). Age-matched mice were immunized s.c. with a synthetic peptide (300 mg) of MOG residues 35-55 (MEVGWYRSPFSRVVH-LYRNGK) (GL Biochem, Shanghai, China). Immunization was performed by mixing the MOG peptide in CFA (Sigma, St. Louis, MO, USA) containing 5 mg/ml of Mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit, MI, USA). Pertussis toxin (200 ng; List Biological Laboratories, Campbell, CA, USA) in phosphate-buffered saline (PBS) was administered i.v. on days 0 and 2. For preventive or treatment protocols of EAE, BA (75 mg/kg; Sigma) or DMSO (as vehicle control) was administered i.p. daily from day 3 pre-or day 12 postimmunization onward. In some experiments, mice were immunized with the MOG peptide and treated with vehicle or BA daily from day 3 pre-immunization. On day 10 post immunization, DLN cells and splenocytes were isolated and re-challenged with the MOG (10 mg/ml) peptide for 3 days. Then, 5 Â 10 6 viable cells were transferred into sublethally irradiated mice (6 Gy). The recipients received pertussis toxin immediately after cell transfer and 2 days later. For some experiments, DLN cells and splenocytes were isolated from EAE mice on day 10 post immunization. Cells were re-challenged with the MOG peptide and then transferred i.v. into sublethally irradiated mice. The recipients received pertussis toxin immediately after cell transfer and 2 days later. Recipients were also injected i.p. with vehicle or BA daily from day 7 post-transfer onward. Mice were examined daily and scored for disease severity by the standard scale: 0, no clinical signs; 1, limp tail; 2, paraparesis (weakness, incomplete paralysis of one or two hind limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, paraplegia with fore limb weakness or paralysis; 5, moribund or death. After the onset of EAE, food and water were provided on the cage floor. To eliminate any diagnostic bias, scores were assigned by researchers blinded to mouse identity. All animal procedures were approved by the Institutional Review Board of the Institute of Health Sciences.
Culture of primary microglia, astrocytes and BV2 cells. Cerebral cortical cells from newborn mice were dissociated by trypsinization and plated in complete DMEM. Two weeks later, culture flasks were shaken at 180-200 r.p.m. at 37 1C and loosely adherent cells were plated and incubated in complete DMEM at 37 1C for 1 h. After extensive washing, adherent microglia were collected. Tightly adherent astrocytes were also collected and incubated in complete DMEM. Purified microglia comprised a cell population in which 95% cells were CD11b-positive cells. Purified astrocytes comprised a cell population in which 95% cells were GFAP-positive cells. For further experiments, primary microglia, astrocytes, or BV2 cells were incubated in complete DMEM and stimulated with or without 100 ng/ml of LPS (Sigma) in the absence or presence of BA (10 or 20 mM), 12-HETE (100 pM), LTB4 (100 nM), LTD4 (100 nM), Zileuton (10 or 20 mM) (all from Sigma) or PD146176 (10 or 20 mM; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Histopathology and scoring. Paraffin-embedded transverse sections (8 mm) of spinal cords were stained with hematoxylin and eosin (H&E) or Luxol fast blue (LFB). Spinal cords stained with H&E were used for scoring inflammation (0: no inflammatory cells; 1: a few scattered inflammatory cells; 2: organization of inflammatory infiltrates around blood vessels; 3: extensive perivascular cuffing with extension into adjacent parenchyma, or parenchymal infiltration). Spinal cords stained with LFB were used for demyelination scoring (0: no demyelination; 1: a few scattered naked axons; 2: small groups of naked axons; 3: large groups of naked axons; 4: confluent foci of demyelination). Scores were generated by one well trained, board-certified histopathologist blind to the groups of mice.
Flow cytometry. Brains and spinal cords were collected from PBS-perfused mice, homogenized and filtered through a 100 mm cell strainer. Cells were collected by centrifugation. Cells were then resuspended in 37% Percoll (GE Amersham, Buckinghamshire, UK), overlayed onto 70% Percoll and then centrifuged. Cells at the 37-70% interface were collected and stained with antibodies (Abs) against mouse antigens such as CD4, CD8, CD45, CXCR3, CCR6 and CD11b (BD Pharmingen, San Diego, CA, USA). Stained cells were washed and analyzed with a FACSAria cytometer (BD Biosciences, San Diego, CA, USA). Quantitative real-time PCR. Total RNA was isolated with TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions and reverse transcribed. Messenger RNA (mRNA) abundance was determined by real-time PCR with SYBR Green master mix (Applied Biosystems, Foster City, CA, USA) and specific primer sets (Table 1) . Data were collected and quantitatively analyzed with an ABI Prism 7900 sequence detection system (Applied Biosystems). Gene expression was assessed by normalizing to b-actin. The control group was normalized to 1 in all figures, and data are presented as folds over control.
Electron microscopy. Mice were anaesthetized and perfused with 0.1 M of PBS followed by 0.1 M of PBS containing 2.5% glutaraldehyde. Lumbar spinal cords were processed, embedded and cut into 1-mm sections. Thin sections were sliced, stained with uranyl acetate and lead citrate, and analyzed by EM (CM120, Phillips, Eindhoven, The Netherlands) by one well trained, board-certified histopathologist blind to the groups of mice.
Immunoblotting. Total cell protein extracts were prepared and separated by 10% SDS-PAGE. Immunoblot analyses were performed by transfer of proteins onto PVDF membranes with a Trans-Blot apparatus (Bio-Rad, Hercules, CA, USA). After 1 h of blocking, membranes were incubated overnight at 4 1C with specific primary Abs with the following dilutions: anti-PPAR (Santa Cruz Biotechnology) and anti-PPARb/d Abs (Abcam) were used at 1 : 300; anti-12-lipoxygenase (Abcam), anti-5-LO, anti-phospho and total ERK1/2, p38 and JNK Abs (all from Cell Signaling Technology, Danvers, MA, USA), and anti-GAPDH (Cell Signaling Technology) Ab were used at 1 : 1000. Membranes were washed and subsequently incubated with appropriate HRP-conjugated secondary Abs for 1 h at room temperature, and washed again. Signals were detected with ECL reagents (Pierce Biotechnology, Rockford, IL, USA).
Immunofluorescence staining. Microglia were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked in 1% BSA, and incubated overnight with rat anti-mouse CD11b (BD Pharmingen) and PPARb/d Abs (Abcam). Subsequently, cells were incubated with fluorochrome-conjugated, goat anti-rat secondary Ab (Invitrogen) and counter stained with DAPI (Beyotime, Nantong, China). Images were taken by a confocal microscope (7CS SP5, Leica, Wetzlar, Germany) equipped with a 63 Â oil immersion objective and analyzed by using LAS AF software (Leica) with an up to 3 Â digital zoom. Minor adjustments to brightness were performed equally across the whole images. Fluorescence intensity was quantitated using ImageJ software (NIH, Bethesda, MD, USA).
Knockdown of 12/15-LO and PPARb/d genes by siRNA. The siRNAs to target murine 12/15-LO, PPARb/d or control siRNA were designed and synthesized (Genepharma, Shanghai, China). siRNA (100 nM) was transfected into the mouse microglia cell line BV2 with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol.
ELISA-based PPARb/d binding assay. Experiments were carried out with an ELISA kit (Cayman Chemicals, Ann Arbor, MI, USA) according to the manufacturer's instructions. Briefly, nuclear extracts were prepared with NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific, Lafayette, CO, USA) according to the manufacturer's instructions. Immunoblotting of GAPDH was used to detect cytoplasmic contamination in nuclear extracts. After that, 50 mg of nuclear extract proteins from vehicle control-, PD146176-, Zileuton-or BA-treated BV2 cells were added to peroxisome proliferator response element dsDNA-coated wells. Then, PPARb/d primary Ab and HRP-conjugated secondary Ab were sequentially added. The OD 450 value was determined with an ELISA reader.
Statistical analyses. The Student's t-test was used to analyze differences between groups. Where appropriate, one-way ANOVA was performed initially to determine whether an overall statistically significant change existed using a twotailed paired or unpaired Student's t-test. Non-parametric Mann-Whitney test was taken to analyze clinical score data between two groups. All tests were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). A P-value o0.05 was considered statistically significant. 
